AML refractory to primary induction with Ida-FLAG has a poor clinical outcome

For over four decades, standard therapy for acute myeloid leukemia (AML) has been the combination of three days of an anthracycline and seven days of cytarabine ( “3 + 7”) [1]. This combination of agents produces complete remission (CR) in approximately 35% to 95% of patients, depending on cytogenetic risk group [2]. Those who do not achieve remission with this regimen can often achieve CR with an intensive reinduction regimen. For example, in patient s who do not achieve CR with “3 + 7”, reinduction with mitoxantrone, etoposide and high dose cytarabine (NOVE-HiDAC) produces an overall response rate of 53% [3].

Source: Leukemia Research - February 19, 2018 Category: Hematology Authors: Simon Kavanagh, Emily Heath, Rose Hurren, Marcela Gronda, Samir H. Barghout, Sanduni U. Liyanage, Thirushi P. Siriwardena, Jaime Claudio, Tong Zhang, Mahadeo Sukhai, Tracy L. Stockley, Suzanne Kamel-Reid, Amr Rostom, Andrzej Lutynski, Dina Khalaf, Anna Ry Tags: Research paper Source Type: research